201 related articles for article (PubMed ID: 15037667)
1. Apomorphine: North American clinical experience.
Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S18-21. PubMed ID: 15037667
[TBL] [Abstract][Full Text] [Related]
2. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
3. Other formulations and future considerations for apomorphine for subcutaneous injection therapy.
Koller W; Stacy M
Neurology; 2004 Mar; 62(6 Suppl 4):S22-6. PubMed ID: 15037668
[TBL] [Abstract][Full Text] [Related]
4. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Factor SA
Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
[TBL] [Abstract][Full Text] [Related]
5. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
6. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
8. Practical considerations in the use of apomorphine injectable.
Bowron A
Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
10. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
11. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
[TBL] [Abstract][Full Text] [Related]
12. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
Rambour M; Moreau C; Salleron J; Devos D; Kreisler A; Mutez E; Simonin C; Annic A; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
[TBL] [Abstract][Full Text] [Related]
13. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
14. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
[TBL] [Abstract][Full Text] [Related]
16. Apomorphine-subcutaneous--Bertek/Britannia.
Drugs R D; 2004; 5(4):211-2. PubMed ID: 15230626
[TBL] [Abstract][Full Text] [Related]
17. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
Stefani A; Stanzione P; Bassi A; Mazzone P; Vangelista T; Bernardi G
J Neural Transm (Vienna); 1997; 104(8-9):895-904. PubMed ID: 9451721
[TBL] [Abstract][Full Text] [Related]
18. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
19. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
Borgemeester RWK; van Laar T
Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
[TBL] [Abstract][Full Text] [Related]
20. [Limits of conventional oral and transdermal medication in Parkinson's disease].
García-Ruiz PJ; Luquin MR
Rev Neurol; 2012; 55 Suppl 1():S3-6. PubMed ID: 23169231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
